RecruitingPhase 3NCT06975865
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Rilzabrutinib(drug)
- Enrollment
- 192 target
- Eligibility
- 10-65 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
- Phoenix Children's Hospital- Site Number : 8400028, Phoenix, Arizona, United States
- University of California San Francisco- Site Number : 8400040, Fresno, California, United States
- Oncology & Hematology Associates of West Broward- Site Number : 8400029, Coral Springs, Florida, United States
- Sylvester Comprehensive Cancer Center- Site Number : 8400020, Miami, Florida, United States
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago, Illinois, United States
- Indiana University Health Riley Hospital for Children- Site Number : 8400056, Indianapolis, Indiana, United States
- Louisiana State University Health Sciences Center - Shreveport- Site Number : 8400037, Shreveport, Louisiana, United States
- University of Maryland School of Medicine - Baltimore- Site Number : 8400041, Baltimore, Maryland, United States
- University of Michigan Health System - Ann Arbor- Site Number : 8400035, Ann Arbor, Michigan, United States
- Southern Specialty Research- Site Number : 8400059, Flowood, Mississippi, United States
- Richmond University Medical Center- Site Number : 8400038, Staten Island, New York, United States
- Baylor College of Medicine- Site Number : 8400055, Houston, Texas, United States
- VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400012, Richmond, Virginia, United States
- Investigational Site Number : 0560003, Brussels, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06975865 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited
- RECRUITINGPHASE1, PHASE2NCT06930703Cannabidiol in Sickle Cell DiseaseIcahn School of Medicine at Mount Sinai